Key result
Bivalirudin cuts serious bleeding vs. heparin during NSTEMI PCI with similar mortality and ischemic outcomes.
Why the study?
The benefit-to-risk profile of bivalirudin versus heparin during PCI in non-ST-segment-elevation myocardial infarction was uncertain, and study-level meta-analyses lacked granularity to provide conclusive answers.
Does bivalirudin reduce 30-day all-cause mortality and serious bleeding compared to heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI?
Meta-Analysis
Individual patient data from 5 randomized trials
Yes
Does bivalirudin reduce 30-day all-cause mortality and serious bleeding compared to heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI?
In NSTEMI patients undergoing PCI, bivalirudin reduces serious bleeding compared to heparin without significant differences in mortality or ischemic events.
Answers are grounded in this paper and cite their sources.
Supports bivalirudin over heparin to reduce bleeding in NSTEMI PCI; confirms no mortality or ischemic trade-off.
BACKGROUND: The benefit:risk profile of bivalirudin versus heparin anticoagulation in patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) is uncertain. Study-level meta-analyses lack granularity to provide conclusive answers. We sought to compare the outcomes of bivalirudin and heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI. METHODS: We performed an individual patient data meta-analysis of patients with non-ST-segment-elevation myocardial infarction in all 5 trials that randomized ≥1000 patients with any myocardial infarction undergoing PCI to bivalirudin versus heparin (MATRIX [Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox], VALIDATE-SWEDEHEART [Bivalirudin Versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies Registry Trial], ISAR-REACT 4 [Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4], ACUITY [Acute Catheterization and Urgent Intervention Triage Strategy], and BRIGHT [Bivalirudin in Acute Myocardial Infarction vs Heparin and GPI Plus Heparin Trial]). The primary effectiveness and safety end points were 30-day all-cause mortality and serious bleeding. Outcomes were consistent regardless of use of a post-PCI bivalirudin infusion or routine lycoprotein IIb/IIIa inhibitor use with heparin and during 1-year follow-up. CONCLUSIONS: In patients with non-ST-segment-elevation myocardial infarction undergoing PCI, procedural anticoagulation with bivalirudin and heparin did not result in significantly different rates of mortality or ischemic events, including stent thrombosis and reinfarction. Bivalirudin reduced serious bleeding compared with heparin arising both from the access site and nonaccess sites.
No takes yet. Share an insight, caveat, or question.
Bikdeli et al. (2023) conducted a meta-analysis in Non-ST-segment-elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI). Bivalirudin vs. Heparin was evaluated on 30-day all-cause mortality (effectiveness) and serious bleeding (safety) (p=<0.0001). Bivalirudin during PCI in NSTEMI reduced serious bleeding compared with heparin without different rates of 30-day mortality or ischemic events.
Synapse has enriched 10 related papers. Consider them for comparative context: